GENFIT (GNFT.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:GNFT - FR0004163111 - Common Stock
5.41 EUR
+0.15 (+2.75%)
Taking everything into account, GNFT scores 2 out of 10 in our fundamental rating. GNFT was compared to 86 industry peers in the Biotechnology industry. The financial health of GNFT is average, but there are quite some concerns on its profitability. GNFT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- GNFT had negative earnings in the past year.
- GNFT had a negative operating cash flow in the past year.
- In multiple years GNFT reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
1.2 Ratios
- GNFT has a better Return On Assets (-17.98%) than 60.47% of its industry peers.
- With a Return On Equity value of -74.24%, GNFT perfoms like the industry average, outperforming 56.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.98% | ||
| ROE | -74.24% | ||
| ROIC | N/A |
ROA(3y)-8.88%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- In the last couple of years the Profit Margin of GNFT has declined.
- GNFT's Operating Margin has declined in the last couple of years.
- GNFT has a better Gross Margin (95.42%) than 93.02% of its industry peers.
- GNFT's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for GNFT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
- GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- GNFT has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, GNFT has more shares outstanding
- Compared to 1 year ago, GNFT has a worse debt to assets ratio.
2.2 Solvency
- GNFT has an Altman-Z score of -1.21. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -1.21, GNFT is not doing good in the industry: 60.47% of the companies in the same industry are doing better.
- GNFT has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
- GNFT's Debt to Equity ratio of 0.10 is fine compared to the rest of the industry. GNFT outperforms 63.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.21 |
ROIC/WACCN/A
WACC7.37%
2.3 Liquidity
- GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
- GNFT has a better Current ratio (3.74) than 69.77% of its industry peers.
- GNFT has a Quick Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
- GNFT has a Quick ratio of 3.74. This is in the better half of the industry: GNFT outperforms 76.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
- The earnings per share for GNFT have decreased strongly by -289.19% in the last year.
- The earnings per share for GNFT have been decreasing by -70.77% on average. This is quite bad
- The Revenue for GNFT has decreased by -45.94% in the past year. This is quite bad
- GNFT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.61% yearly.
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
3.2 Future
- Based on estimates for the next years, GNFT will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.44% on average per year.
- GNFT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.87% yearly.
EPS Next Y-192.65%
EPS Next 2Y-97.6%
EPS Next 3Y-36.76%
EPS Next 5Y-29.44%
Revenue Next Year-34.41%
Revenue Next 2Y-21.78%
Revenue Next 3Y-8%
Revenue Next 5Y-1.87%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- GNFT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as GNFT's earnings are expected to decrease with -36.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-97.6%
EPS Next 3Y-36.76%
5. Dividend
5.1 Amount
- GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:GNFT (1/22/2026, 10:34:12 AM)
5.41
+0.15 (+2.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20 2025-11-20
Earnings (Next)02-26 2026-02-26/amc
Inst Owners6.03%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap270.52M
Revenue(TTM)45.41M
Net Income(TTM)-38.96M
Analysts90
Price Target8.79 (62.48%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.73%
PT rev (3m)-1.49%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-180%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-28.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.96 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.16 | ||
| P/tB | 127.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.91
BVpS1.05
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.98% | ||
| ROE | -74.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% | ||
| FCFM | N/A |
ROA(3y)-8.88%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 188.34% | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z | -1.21 |
F-Score2
WACC7.37%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-192.65%
EPS Next 2Y-97.6%
EPS Next 3Y-36.76%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
Revenue Next Year-34.41%
Revenue Next 2Y-21.78%
Revenue Next 3Y-8%
Revenue Next 5Y-1.87%
EBIT growth 1Y-217.08%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year-89.66%
EBIT Next 3Y-36.71%
EBIT Next 5YN/A
FCF growth 1Y87.75%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.86%
OCF growth 3Y-46.21%
OCF growth 5YN/A
GENFIT / GNFT.PA FAQ
What is the fundamental rating for GNFT stock?
ChartMill assigns a fundamental rating of 2 / 10 to GNFT.PA.
What is the valuation status for GNFT stock?
ChartMill assigns a valuation rating of 0 / 10 to GENFIT (GNFT.PA). This can be considered as Overvalued.
Can you provide the profitability details for GENFIT?
GENFIT (GNFT.PA) has a profitability rating of 2 / 10.
What is the expected EPS growth for GENFIT (GNFT.PA) stock?
The Earnings per Share (EPS) of GENFIT (GNFT.PA) is expected to decline by -192.65% in the next year.